Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neuromodulation to Overcome Severe Restless Legs Syndrome
Sponsor: Marshall Holland
Summary
This prospective, single-center, first-in-indication feasibility study will evaluate the safety and preliminary effectiveness of spinal cord stimulation (SCS) for the treatment of severe, treatment-refractory primary Restless Legs Syndrome (RLS). Participants will undergo implantation of the Saluda Medical Evoke® Spinal Cord Stimulation System and will be followed for 24 months with clinical, neurophysiological, and patient-reported outcome assessments.
Official title: Neuromodulation to Overcome Severe Restless Legs Syndrome (NO RLS)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2027-10
Completion Date
2034-10
Last Updated
2026-10-09
Healthy Volunteers
No
Interventions
Spinal Cord Stimulation
Implantation of the FDA-approved Saluda Medical Evoke® Spinal Cord Stimulation System with Smartloop® Technology. Two percutaneous epidural leads will be implanted in the thoracic spine (T7-T10 region) and programmed to provide chronic spinal cord stimulation for treatment of severe RLS symptoms.
Locations (1)
UAB Hospital
Birmingham, Alabama, United States